

**Supplementary Fig. 1. Sarmentosin and sorafenib were effective in HepG2 cells.** (A) HepG2 cells were treated with DMSO (0.02%, w/v), or sorafenib (diluted in DMSO) at different concentrations for 24 h to determine the best dosage of sorafenib *in vitro*. Cell viability was determined with a CCK-8 assay. Data are percentage of control value (*n* = 6). \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.005 vs. control group. (B) The indicated dosage of sarmentosin and sorafenib were applied to HepG2. Cell mortality was assessed by trypan blue staining (*n* = 3). Cells marked in blue are dead.